Background
Phenytoin sodium is a long off-patent anti-epilepsy drug with a narrow therapeutic index, meaning patients stabilised on a particular manufacturer’s capsules must remain on that product. Pfizer had supplied the capsules under the brand name Epanutin, subject to NHS price controls under the Pharmaceutical Price Regulation Scheme. In September 2012, Pfizer sold the marketing authorisation to Flynn Pharma for £1 and entered an exclusive distribution agreement. Flynn debranded the product, withdrawing it from price controls, then immediately raised prices. Flynn’s average selling price to the NHS rose by up to 2,682% overnight. The price of a pack of 100mg capsules — accounting for roughly 75% of demand — climbed from £2.21 to £59.53. Annual NHS expenditure on the drug surged from £2.3 million in 2012 to £50 million in 2013. Contemporaneous internal documents showed both companies were aware of the ethical and reputational risks and that Pfizer had interposed Flynn specifically to deflect regulatory scrutiny and circumvent the price-control regime.
The CMA (through its predecessor the OFT) opened an investigation in 2013. Its first decision in December 2016 found that Pfizer and Flynn each abused a dominant position through unfair pricing contrary to section 18 of the Competition Act 1998. That decision was challenged, and by the time of the first Court of Appeal judgment (Pfizer v CMA [2020] EWCA Civ 339, Phenytoin I), the court confirmed that the CMA had failed adequately to examine evidence relating to phenytoin tablets as price comparators and the economic value attributable to patient benefit, and remitted the matter for redetermination. The CMA issued a second Decision on 21 July 2022, again finding abuse and imposing substantial penalties — approximately £63 million on Pfizer and significant sums on Flynn. On appeal, the Competition Appeal Tribunal (CAT) in [2024] CAT 65 set aside the 2022 Decision, finding fundamental procedural failures including bias, predetermined outcome, and reversal of the burden of proof. Rather than remit to the CMA for a third time, the CAT retook the decision itself and once more concluded that both companies had abused their dominant positions, affirming penalties with only a minor downward adjustment to Pfizer’s fine (from £63 million to £62.37 million).
Both Pfizer and Flynn appealed the CAT’s retaken decision to the Court of Appeal, contending it was itself procedurally unfair. The CMA cross-appealed, arguing that the CAT had wrongly set aside the original 2022 Decision and seeking its restoration. The hearing took place before Lords Justice Green, Snowden, and Zacaroli in January 2026.
The Court’s Holding
The Court of Appeal confirmed, at the outset of its analysis, that the CAT’s retaken decision was vitiated by procedural unfairness, accepting the force of Pfizer and Flynn’s submissions on that issue. That agreement meant the central question before the Court became the CMA’s cross-appeal: whether the CAT had been wrong to find fundamental flaws in the 2022 CMA Decision, and if so, whether that Decision should be restored rather than the matter remitted for yet another round of administrative proceedings. The Court conducted a detailed review of the applicable legal framework governing unfair excessive pricing under section 18 CA 1998 and the EU jurisprudence derived from United Brands v Commission, confirming that the Cost Plus methodology remains a valid primary tool for assessing abuse, that no single category of evidence is automatically dispositive, and — critically — that the CMA formally confirmed before the Court that prices above Cost Plus are neither per se illegal nor presumed to be abusive.
The Court endorsed the two-stage analytical framework adopted by the CAT in Le Patourel v BT [2024] CAT 76: at stage one, the computation of Cost Plus and the margin of actual selling price above it is treated as a predominantly accountancy-driven exercise; at stage two, all evidence going to whether that margin is justified — including economic value, comparables, patient benefit, and competitive benchmarks — is evaluated in a single overall assessment of fairness. This approach was described as “cleaner and more efficient” and had already been endorsed by this Court in refusing permission to appeal in Le Patourel. The Court also confirmed the principles established in Cinven Capital Management v CMA [2025] EWCA Civ 578, reinforcing that Cost Plus can in an appropriate case serve as a valid and sufficient proxy for what a fair, workably competitive price would be, even when derived from analysis of a dominant undertaking operating in a non-competitive market.
Against that framework, the Court assessed whether the CAT’s characterisation of the CMA Decision as fundamentally flawed — on grounds including bias, predetermined outcome, and failure fairly to evaluate exculpatory evidence — was itself correct. The companies did not contest the first part of the CAT’s judgment (which had allowed their appeals against the 2022 Decision); the dispute centred on whether those findings justified setting aside the Decision in its entirety and, if the retaken decision also fell away for procedural unfairness, on what outcome should follow. The Court’s analysis of whether the 2022 Decision should be restored, or whether a further remittal was required, proceeded through detailed examination of the CAT’s specific findings of error.
Key Takeaways
- Prices above Cost Plus are not per se unlawful or presumed abusive under section 18 CA 1998 — the CMA formally confirmed this position before the Court, and the Court endorsed it.
- The two-stage Le Patourel framework — Cost Plus computation at stage one, holistic fairness evaluation including economic value at stage two — is the approved analytical structure for excessive pricing cases before the CAT and CMA.
- A CAT decision to retake an administrative decision after setting one aside on procedural grounds is itself subject to strict procedural fairness requirements; the Court confirmed the CAT’s retaken finding was vitiated by procedural unfairness.
- Internal documents showing deliberate strategy to circumvent price regulation, awareness of patient risk, and intent to extract supra-competitive profits are highly probative of intentional abuse in excessive pricing cases.
- Debranding a product to withdraw it from a price-control scheme and then dramatically increasing prices — without any change in costs, innovation, or patient benefit — is the paradigm case of unjustifiable opportunistic pricing under competition law.
Why It Matters
This decision is the latest chapter in one of the most significant pharmaceutical competition enforcement cases in UK history, spanning over a decade of litigation between the CMA and two major industry players. The case has repeatedly tested the boundaries of excessive pricing law — an area where the line between lawful profit-seeking and unlawful abuse is notoriously difficult to draw — and each iteration has refined the analytical tools available to regulators and courts. The Court’s endorsement of the Le Patourel two-stage framework and its restatement that Cost Plus can be a sufficient proxy for workably competitive pricing gives the CMA clearer methodological ground for future enforcement, while the confirmation that prices above Cost Plus carry no presumption of illegality provides a measure of reassurance to pharmaceutical companies that not every margin premium will attract liability.
More broadly, the case underscores that dominant pharmaceutical companies cannot insulate themselves from competition law scrutiny by restructuring supply chains to remove products from price-control regimes. The facts — price increases of up to 2,682%, extraction of tens of millions of pounds from a constrained NHS budget, and documented internal awareness of the ethical and competitive risks — represent what the CAT called “extreme” and intentional infringements. For practitioners advising companies in regulated sectors, the judgment is a reminder that internal documents recording strategic deliberations, ethical debates, and awareness of regulatory risk will receive close judicial scrutiny if pricing practices are later challenged.